p63 expression may be a marker of basal/progenitor cells and a diagnostic marker in skin tumors. p63 expression is not related to p53 expression in these tumors. This study points to a putative role of survivin and hTERT in the development of certain skin cancers. In addition, our data support the concept of porokeratosis being a premalignant condition.
PurposeThe interaction of programmed death receptor 1 (PD-1) and its ligand, programmed death
receptor ligand 1 (PD-L1), negatively regulates immune responses. This study aimed to
clarify PD-L1 expression levels in breast cancer through immunohistochemistry (IHC) and
to evaluate associations between these findings and clinicopathologic variables,
including prognosis.MethodsPD-L1 expression was analyzed using IHC on tissue microarrays of 465 invasive breast
carcinomas.ResultsHigh PD-L1 expression was demonstrated in 63 of 465 tumors (13.5%). High PD-L1
expression was significantly associated with high histologic grade
(p<0.001), negative lymph nodes (p=0.011),
early pathologic stage (p=0.025), high tumor-infiltrating lymphocyte
(TIL) (p<0.001) counts, negative estrogen receptor
(p<0.001) and progesterone receptor (p=0.002)
expression, positive human epidermal growth factor receptor 2 (HER2)
(p=0.003), cytokeratin 5/6 (p=0.011), epidermal growth
factor receptor (p<0.001), and p53
(p<0.001) expression, and high Ki-67 proliferating index
(p<0.001). Based on intrinsic subtypes, high PD-L1 expression
and high TIL counts were significantly associated with the HER2 and triple-negative
basal type (p<0.001). PD-L1 expression was significantly
associated with better disease-free survival (DFS) (p=0.041) and
overall survival (OS) (p=0.026) in the univariate analysis, but not in
the multivariate analysis. Higher TIL levels was an independent prognostic factor for
decreased disease progression (hazard ratio [HR], 2.389; 95% confidence interval [CI],
1.284–4.445; p=0.006) and overall death (HR, 3.666; 95% CI,
1.561–8.607; p=0.003).ConclusionPD-L1 protein expression in breast cancer is associated with better DFS and OS, but is
not an independent prognostic factor. High PD-L1 expression was significantly associated
with high TIL levels. This finding has important implications for antibody therapies
targeting the PD-1/PD-L1 signaling mechanism in breast cancer.
The prevalence (90%) of the BRAF (V600E) mutation in this study is the highest ever reported, confirming the key role of this mutation in PTC tumorigenesis. The BRAF (V600E) mutation was associated with aggressive clinical behaviors including extrathyroid invasion, lymph nodal metastasis and tumor multifocality. The PNA clamp real-time PCR method for the BRAF (V600E) mutation detection is sensitive and is applicable in a clinical setting.
PurposeSomatic mutations of the chromatin remodeling AT-rich interactive domain 1A (SWI-like) gene (ARID1A) have been identified in many human cancers, including breast cancer. The purpose of this study was to evaluate the nuclear expression of ARID1A in breast cancers by immunohistochemistry (IHC) and to correlate the findings to clinicopathologic variables including prognostic significance.MethodsIHC was performed on tissue microarrays of 476 cases of breast cancer. Associations between ARID1A expression and clinicopathologic characteristics and molecular subtype were retrospectively analyzed.ResultsLow expression of ARID1A was found in 339 of 476 (71.2%) cases. Low expression of ARID1A significantly correlated with positive lymph node metastasis (p=0.027), advanced pathologic stage (p=0.001), low Ki-67 labeling index (p=0.003), and negative p53 expression (p=0.017). The ARID1A low expression group had significantly shorter disease-free and overall survival than the ARID1A high expression group (p<0.001 and p<0.001, respectively). Multivariate analysis demonstrated that low expression of ARID1A was a significant independent predictive factor for poor disease-free and overall survival in patients with breast cancer (disease-free survival: hazard ratio, 0.38, 95% confidence interval [CI], 0.20-0.73, p=0.004; overall survival: hazard ratio, 0.11, 95% CI, 0.03-0.46, p=0.003). In patients with luminal A type disease, patients with low ARID1A expression had significantly shorter disease-free and overall survival rates than patients with high ARID1A expression (p=0.022 and p=0.018, respectively).ConclusionLow expression of ARID1A is an independent prognostic factor for disease-free and overall survival in breast cancer patients and may be associated with luminal A type disease. Although the biologic function of ARID1A in breast cancer remains unknown, low expression of ARID1A can provide valuable prognostic information.
Endoscopic forceps biopsy was insufficient for a definitive diagnosis and therapeutic planning in patients with GEN. ER should be considered as not only definitive treatment but also a procedure for a precise histological diagnosis for lesions initially assessed as GEN by forceps biopsy specimens.
PurposeThe enhancer of zeste homologue 2 (EZH2) is a catalytic subunit of the polycomb repressive complex 2, a highly conserved histone methyltransferase. EZH2 overexpression has been implicated in various malignancies, including breast cancer, where is associated with poor outcomes. This study aims to clarify nuclear EZH2 expression levels in breast cancers using immunohistochemistry (IHC) and correlate these findings with clinicopathologic variables, including prognostic significance.MethodsIHC was performed on tissue microarrays of 432 invasive ductal carcinoma (IDC) tumors. Associations between EZH2 expression, clinicopathologic characteristics, and molecular subtype were retrospectively analyzed. The relationship between EZH2 protein expression in normal breast tissue and ductal carcinoma in situ (DCIS) was also assessed.ResultsHigh EZH2 expression was demonstrated in 215 of 432 tumors (49.8%). EZH2 was more frequently expressed in DCIS and IDC than in normal breast tissue (p=0.001). High EZH2 expression significantly correlated with high histologic grade (p<0.001), large tumor size (p=0.014), advanced pathologic stage (p=0.006), negative estrogen receptor status (p<0.001), positive human epidermal growth factor receptor 2 (HER2) status (p<0.001), high Ki-67 staining index (p<0.001), positive cytokeratin 5/6 status (p=0.003), positive epidermal growth factor receptor status (p<0.001), and positive p53 status (p<0.001). Based on molecular subtypes, high EZH2 expression was significantly associated with HER2-negative luminal B, HER2-positive luminal B, and HER2 type and triple-negative basal cancers (p<0.001). In patients with luminal A, there was a significant trend toward shorter overall survival for those with tumors having high EZH2 expression compared to those with tumors having low EZH2 expression (p=0.045).ConclusionEZH2 is frequently upregulated in breast malignancies, and it may play an important role in cancer development and progression. Furthermore, EZH2 may be a prognostic marker, especially in patients with luminal A cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.